BGB-A317-210
Completed
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Study Overview
Sex:
All 
Age: 18 Years / N/A
No Study Documents
Study Overview
Sex:
All
Age: 18 Years / N/A
No Study Documents